产品活性:ARA290 enhances the proliferation, migration, and resistance to H2O2-induced apoptosis of endothelial colony-forming cells (ECFCs)[1]. ARA290 is an EPO-alog peptide without hematopoietic side-effects but may have neurotrophic and antidepressant effects[2]. ...
However, its clinical application is limited by hematopoietic side effects. ARA290, a non-hematopoietic derivative of EPO, selectively activates the innate repair receptor (IRR) and replicates these protective effects without the associated hematopoietic complications. Cadmium (Cd), a prevalent ...
In addition, the agents may exert other anti-inflammatory effects. Since these agents are all associated with a wide spectrum of toxic side effects, the natural dietary supplement compositions of the present disclosure could provide a non-toxic alternative to NSAIDs. Cancer Cyclooxygenases have been...
2005, 23, 277–290. [Google Scholar] [CrossRef] Stock, M.G.; Akita, M.; Krehbiel, P.R.; Rison, W.; Edens, H.E.; Kawasaki, Z.; Stanley, M.A. Continuous broadband digital interferometry of lightning using a generalized cross-correlation algorithm. J. Geophys. Res. Atmos. 2014, ...
In HSBC's consolidated financial statements, the fair value differences of $8,290m in respect of HSBC Continental Europe and $12,768m in respect of HSBC Finance Corporation were recognised in the merger reserve. The merger reserve created on the acquisition of HSB...
Chronic neuropathic pain is a debilitating disease and current treatment options are either of limited efficacy or are hampered by the development of serious side effects. A novel pharmacological treatment option is the non-hematopoietic erythropoietin analog ARA 290, a small peptide acting at the ...
Although erythropoietin ameliorates experimental type 2 diabetes with neuropathy, serious side effects limit its potential clinical use. ARA 290, a nonhematopoietic peptide designed from the structure of erythropoietin, interacts selectively with the innate repair receptor that mediates tissue protection. ARA...
Although erythropoietin ameliorates experimental type 2 diabetes with neuropathy, serious side effects limit its potential clinical use. ARA 290, a nonhematopoietic peptide designed from the structure of erythropoietin, interacts selectively with the innate repair receptor that mediates tissue protection. ARA...
Given the excellent safety profile while reducing neuropathy symptoms, the prospects of ARA 290 treatment in sarcoid neuropathy seem promising. The long-lasting beneficial effects of ARA 290 on both pain-related and non-pain-related symptoms in sarcoidosis patients prompt additional studies on ...
It has been suggested previously that erythropoietin reduces disease activity in RA,12 but given the side effects of administering high doses of erythropoietin, this treatment option has not been further investigated. Objectives To assess the safety and efficacy of ARA290, a non-hematopoietic ...